Endocardial ablation is a medical procedure employed to treat certain heart rhythm disorders, specifically those arising from abnormal electrical pathways within the heart. Also known as catheter ablation, this minimally invasive technique involves the use of a catheter—a thin, flexible tube—that is threaded through blood vessels to reach the heart. Once in position, the catheter delivers controlled bursts of energy, often in the form of radiofrequency or cryotherapy, to selectively destroy or modify tissue responsible for erratic electrical signals. Endocardial ablation is commonly used to address conditions such as atrial fibrillation, atrial flutter, and supraventricular tachycardia. By disrupting the abnormal pathways causing irregular heartbeats, this procedure aims to restore a normal rhythm and alleviate symptoms like palpitations, fatigue, and shortness of breath. Endocardial ablation has proven to be an effective and increasingly utilized intervention, offering patients a potential solution for managing and improving their cardiac health. As with any medical procedure, individual cases may vary, and healthcare professionals will carefully evaluate each patient's specific condition to determine the most appropriate course of treatment
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation